Molecular Cancer

Article	Citations
BRD9-p53-E2F1 circuit orchestrates cell growth and DNA damage repair in gastric cancer	1275
LMTK3 regulation of EV biogenesis and cargo sorting promotes tumour growth by reducing monocyte infiltration and driving pro-tumourigenic macrophage polarisation in breast cancer	1049
Spatial and functional dissection of cancer-associated fibroblasts-mediated immune modulation in H. pylori-associated gastric cancer	1022
Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma	794
ERK mediates interferon gamma-induced melanoma cell death	760
CRISPR based therapeutics: a new paradigm in cancer precision medicine	756
The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis	661
Correction to: The function and mechanisms of action of circular RNAs in Urologic Cancer	639
Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications	615
Immunotherapies in rare cancers	610
Neoadjuvant immunotherapy in squamous cell carcinoma of the head and neck: current evidence and future perspectives	608
Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells	557
Chaperone-mediated autophagy modulates Snail protein stability: implications for breast cancer metastasis	554
Correction: m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC	475
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway	432
Integrative gene network and functional analyses identify a prognostically relevant key regulator of metastasis in Ewing sarcoma	399
TGF-β signaling promotes cervical cancer metastasis via CDR1as	375
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research	342
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression	337
The miR-23a/27a/24 − 2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer	325
circNOX4 activates an inflammatory fibroblast niche to promote tumor growth and metastasis in NSCLC via FAP/IL-6 axis	312
Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacy	312
Exosomal circSIPA1L3-mediated intercellular communication contributes to glucose metabolic reprogramming and progression of triple negative breast cancer	296
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers	294
Proteogenomic characterization of molecular and cellular targets for treatment-resistant subtypes in locally advanced cervical cancers	271

The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments	267
E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer	265
Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery	260
EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3	256
Engineered multifunctional nanoparticles for enhanced radiation therapy: three-in-one approach for cancer treatment	241
The epigenetic regulatory mechanism of PIWI/piRNAs in human cancers	240
LINC02159 promotes non-small cell lung cancer progression via ALYREF/YAP1 signaling	236
Correction: Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis	236
Bidirectional role of neutrophils in tumor development	233
Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment	229
Biomolecular phase separation in tumorigenesis: from aberrant condensates to therapeutic vulnerabilities	225
Efferocytosis: the art of cellular clearance and novel perspectives in disease therapy	222
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state	205
Myofibroblast-derived extracellular vesicles facilitate cancer stemness of hepatocellular carcinoma via transferring ITGA5 to tumor cells	204
Nuclear receptors as novel regulators that modulate cancer radiosensitivity and normal tissue radiotoxicity	203
Increased plasma concentrations of acyl-coenzyme A binding protein (ACBP) predict future lung cancer development in smokers at risk of cardiovascular disease	195
Biofilm formation by the host microbiota: a protective shield against immunity and its implication in cancer	193
Effects of RNA methylation on Tumor angiogenesis and cancer progression	191
Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection	188
PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN	185
NK cells are never alone: crosstalk and communication in tumour microenvironments	181
Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer	180
KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis	170
Nanotechnology-leveraged CRISPR/Cas systems: icebreaking in trace cancer-related nucleic acids biosensing	170
LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling	170
Tumor cell-intrinsic MELK enhanced CCL2-dependent immunosuppression to exacerbate hepatocarcinogenesis and confer resistance of HCC to radiotherapy	169
Emerging roles of tRNA-derived fragments in cancer	167
Therapy-induced senescent tumor cell-derived extracellular vesicles promote colorectal cancer progression through SERPINE1-mediated NF-κB p65 nuclear translocation	163
Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer	162
Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes	162
Insights into N6-methyladenosine and programmed cell death in cancer	158
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments	157
Gold nanoparticles and gold nanorods in the landscape of cancer therapy	157
Nanomedicine in Cancer Therapeutics: Current Perspectives from Bench to Bedside	155
Dissecting small cell carcinoma of the esophagus ecosystem by single-cell transcriptomic analysis	155
Biologically targeted dual adaptive and innate nano-Immunotherapy for clear cell renal cell carcinoma treatment	154
Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy	153
Context-dependent impact of type I interferon signaling in cancer	152
Correction: CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling	152
Deubiquitination of CDC6 by OTUD6A promotes tumour progression and chemoresistance	150
Crosstalk between autophagy and microbiota in cancer progression	149
Retraction Note: Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis	146
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer	146
lncRNAs: the unexpected link between protein synthesis and cancer adaptation	145
Loss of TACC2 impairs chemokine CCL3 and CCL4 expression and reduces response to anti-PD-1 therapy in soft tissue sarcoma	145
CircAKT3 promotes prostate cancer proliferation and metastasis by enhancing the binding of RPS27A and RPL11	145
A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer	144
Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies	139
Correction: Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT1	138
m6A methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinoma	132

Targeting HNRNPU to overcome cisplatin resistance in bladder cancer	132
Identification of multidrug chemoresistant genes in head and neck squamous cell carcinoma cells	132
The application of organoids in treatment decision-making for digestive system cancers: progress and challenges	132
Neuroscience of cancer: unraveling the complex interplay between the nervous system, the tumor and the tumor immune microenvironment	131
Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition	130
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy	128
A positive feedback loop between PFKP and c-Myc drives head and neck squamous cell carcinoma progression	127
Circular RNA circCLASP2 promotes nasopharyngeal carcinoma progression through binding to DHX9 to enhance PCMT1 translation	127
Long non-coding RNA NORAD/miR-224-3p/MTDH axis contributes to CDDP resistance of esophageal squamous cell carcinoma by promoting nuclear accumulation of β-catenin	126
Exosome circATP8A1 induces macrophage M2 polarization by regulating the miR-1-3p/STAT6 axis to promote gastric cancer progression	125
Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring	123
Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy	123
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing	122
Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer	121
Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors	120
EMT/MET plasticity in cancer and Go-or-Grow decisions in quiescence: the two sides of the same coin?	119
Molecular mechanisms of tumor resistance to radiotherapy	118
Activation-induced cytidine deaminase causes recurrent splicing mutations in diffuse large B-cell lymphoma	117
Correction: Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy	117
Correction: MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer	117
A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions	116
Cancer neuroscience in head and neck: interactions, modulation, and therapeutic strategies	116
A novel peptide encoded by N6-methyladenosine modified circMAP3K4 prevents apoptosis in hepatocellular carcinoma	115
Inhibition of 6-phosphogluconate dehydrogenase suppresses esophageal squamous cell carcinoma growth and enhances the anti-tumor effects of metformin via the AMPK/mTOR pathway	114
Targeting metastasis in paediatric bone sarcomas	114
A positive feedback circuit driven by m6A-modified circular RNA facilitates colorectal cancer liver metastasis	113
Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients	111
Co-transcriptional R-loops-mediated epigenetic regulation drives growth retardation and docetaxel chemosensitivity enhancement in advanced prostate cancer	110
The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin	110
CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling	110
Multifaceted roles for BCL3 in cancer: a proto-oncogene comes of age	110
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges	109
CDC6 is a prognostic biomarker and correlated with immune infiltrates in glioma	109
PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives	106
N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1	106
Multimodal sequencing of neoadjuvant nivolumab treatment in hepatocellular carcinoma reveals cellular and molecular immune landscape for drug response	106
Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response	104
An exosome-based liquid biopsy signature for pre-operative identification of lymph node metastasis in patients with pathological high-risk T1 colorectal cancer	103
CircNFIB inhibits tumor growth and metastasis through suppressing MEK1/ERK signaling in intrahepatic cholangiocarcinoma	103
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors	103
Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALL	103
Deciphering a profiling based on multiple post-translational modifications functionally associated regulatory patterns and therapeutic opportunities in human hepatocellular carcinoma	101
OLFM4 promotes the progression of intestinal metaplasia through activation of the MYH9/GSK3β/β-catenin pathway	101
Hypoxia-induced lncRNA STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal cancer progression by preventing m6A-mediated degradation of STEAP3 mRNA	100
Metabolic checkpoints in immune cell reprogramming: rewiring immunometabolism for cancer therapy	99
Retraction Note: Systematic analyses reveal long non-coding RNA (PTAF)-mediated promotion of EMT and invasion-metastasis in serous ovarian cancer	99
Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the “Smart” exosome nanoparticle therapy	99
Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond	99
Correction: Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway	97
Integration of pan-omics technologies and three-dimensional in vitro tumor models: an approach toward drug discovery and precision medicine	97
Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective	95
A high proportion of germline variants in pediatric chronic myeloid leukemia	95
PRMT7: a survive-or-die switch in cancer stem cells	95
Unveiling the immunomodulatory dance: endothelial cells’ function and their role in non-small cell lung cancer	94
CircPVT1: a pivotal circular node intersecting Long Non-Coding-PVT1 and c-MYC oncogenic signals	93
DNA methylation-associated dysregulation of transfer RNA expression in human cancer	93
BIRC2 blockade facilitates immunotherapy of hepatocellular carcinoma	92
Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT1	91
Biological and pharmacological roles of m6A modifications in cancer drug resistance	91
CircVAPA promotes small cell lung cancer progression by modulating the miR-377-3p and miR-494-3p/IGF1R/AKT axis	90
Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination	89
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better	89
Epithelial-to-mesenchymal transition (EMT) and cancer metastasis: the status quo of methods and experimental models 2025	88
Interleukin-21 receptor signaling promotes metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma by inducing immunosuppressive IgA+ B cells	88
Identification of HSP90B1 in pan-cancer hallmarks to aid development of a potential therapeutic target	88
Intracellular osteopontin protects from autoimmunity-driven lymphoma development inhibiting TLR9-MYD88-STAT3 signaling	88
Role of a novel circRNA-CGNL1 in regulating pancreatic cancer progression via NUDT4–HDAC4–RUNX2–GAMT-mediated apoptosis	88
Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment	87
Anti irradiation nanoparticles shelter immune organ from radio-damage via preventing the IKK/IκB/NF-κB activation	87
Exosomal miR-4745-5p/3911 from N2-polarized tumor-associated neutrophils promotes gastric cancer metastasis by regulating SLIT2	86
Inflammation in cancer: therapeutic opportunities from new insights	85
Recent advances of small extracellular vesicle biomarkers in breast cancer diagnosis and prognosis	85
Glioma targeted therapy: insight into future of molecular approaches	84
Correction: Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance	83
Correction: Expression and inactivation of glycogen synthase kinase 3 alpha/ beta and their association with the expression of cyclin D1 and p53 in oral squamous cell carcinoma progression	83
Pangaea Oncology, Dexeus University Hospital: bridging preclinical and clinical research	83
Retraction Note to: LncRNA PVT1 triggers Cyto-protective autophagy and promotes pancreatic ductal adenocarcinoma development via the miR-20a-5p/ULK1 Axis	81
Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors	80
Circular RNA ACVR2A promotes the progression of hepatocellular carcinoma through mir-511-5p targeting PI3K-Akt signaling pathway	80
An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer	79

SELP+ TEC:CD8+ T cell crosstalk associates with improved radiotherapy efficacy in cervical cancer	79
Shifting landscapes of gender equity in oncology journals: a decade of authorship trends	79
Immune dynamics shaping pre-metastatic and metastatic niches in liver metastases: from molecular mechanisms to therapeutic strategies	78
Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions	78
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development	76
Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency	76
Exploring molecular and cellular mechanisms of Pre-Metastatic niche in renal cell carcinoma	76
Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy	76
Circular RNA circPOLR2A promotes clear cell renal cell carcinoma progression by facilitating the UBE3C-induced ubiquitination of PEBP1 and, thereby, activating the ERK signaling pathway	75
Correction: Proteogenomic characterization of molecular and cellular targets for treatment‑resistant subtypes in locally advanced cervical cancers	75
Microbiome-targeted nanoplatforms and engineering approaches in breast cancer therapy	75
Single-cell RNA sequencing reveals immune microenvironment niche transitions during the invasive and metastatic processes of ground-glass nodules and part-solid nodules in lung adenocarcinoma	74
YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment	74
Proteomics technologies for cancer liquid biopsies	74
Lysyl hydroxylase LH1 promotes confined migration and metastasis of cancer cells by stabilizing Septin2 to enhance actin network	74
Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells	74
Lung-specific metastasis: the coevolution of tumor cells and lung microenvironment	73
The role of m6A RNA methylation in cancer metabolism	73
A comprehensive overview of ovarian cancer stem cells: correlation with high recurrence rate, underlying mechanisms, and therapeutic opportunities	73
Cuproptosis correlates with immunosuppressive tumor microenvironment based on pan-cancer multiomics and single-cell sequencing analysis	72
Targeting TGF-β signal transduction for fibrosis and cancer therapy	71
Retraction Note: Quercetin-induced miR-200b-3p regulates the mode of self-renewing divisions in pancreatic cancer	71
CircHERC1 promotes non-small cell lung cancer cell progression by sequestering FOXO1 in the cytoplasm and regulating the miR-142-3p-HMGB1 axis	71
Exploiting innate immunity for cancer immunotherapy	71
Tumor metabolic regulators: key drivers of metabolic reprogramming and the promising targets in cancer therapy	71
Correction: The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin	70
Essential gene screening identifies the bromodomain-containing protein BRPF1 as a new actionable target for endocrine therapy-resistant breast cancers	68
CircRNA aptamer targets IGF2BP2 to overcome acquired BETi resistance	68
A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer	66
Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo	66
PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma	66
Clustering cancers by shared transcriptional risk reveals novel targets for cancer therapy	66
Single-cell RNA-seq reveals the genesis and heterogeneity of tumor microenvironment in pancreatic undifferentiated carcinoma with osteoclast-like giant-cells	65
The circSPON2/miR-331-3p axis regulates PRMT5, an epigenetic regulator of CAMK2N1 transcription and prostate cancer progression	65
Circulating cell-free DNA methylation patterns as non-invasive biomarkers to monitor colorectal cancer treatment efficacy without referencing primary site mutation profiles	65
Expression of mTOR in normal and pathological conditions	65
LINE-1 promotes tumorigenicity and exacerbates tumor progression via stimulating metabolism reprogramming in non-small cell lung cancer	64
Hijacking of the nervous system in cancer: mechanism and therapeutic targets	64
i-CRISPR: a personalized cancer therapy strategy through cutting cancer-specific mutations	63
Targeting m7G-enriched circKDM1A prevents colorectal cancer progression	63
Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia	63
Mapping cancer biology in space: applications and perspectives on spatial omics for oncology	62
Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells	62
Wnt signaling in cancer: from biomarkers to targeted therapies and clinical translation	61
The application of organoids in investigating immune evasion in the microenvironment of gastric cancer and screening novel drug candidates	61
A novel protein AXIN1-295aa encoded by circAXIN1 activates the Wnt/β-catenin signaling pathway to promote gastric cancer progression	60
The University of Kansas Cancer Center (KUCC), an NCI designated comprehensive cancer center	60
Extracellular vesicles in tumor immunity: mechanisms and novel insights	60
Mir-483-5p-mediated activating of IGF2/H19 enhancer up-regulates IGF2/H19 expression via chromatin loops to promote the malignant progression of hepatocellular carcinoma	60
Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T	60
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer	60
Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches	60
Lipid reprogramming and ferroptosis crosstalk in clear cell renal cell carcinoma: metabolic vulnerabilities and therapeutic targeting	59
Correction: circCYP24A1 facilitates esophageal squamous cell carcinoma progression through binding PKM2 to regulate NF-κB-induced CCL5 secretion	59
Correction: ZEB1 transcriptionally regulated carbonic anhydrase 9 mediates the chemoresistance of tongue cancer via maintaining intracellular pH	59
HPGD induces ferroptosis and autophagy to suppress esophageal squamous cell carcinoma through the LXA4–ERK1/2–U2AF2–TFRC axis	59
Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs	58
​​The immune microenvironment of pathogen-associated cancers and current clinical therapeutics	58
circRNAs shed light on cancer diagnosis and treatment	58
The single cell transcriptional landscape of esophageal adenocarcinoma and its modulation by neoadjuvant chemotherapy	57
Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop	57
A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer	57
Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations	57
Correction: Comprehensive review of CRISPR‑based gene editing: mechanisms, challenges, and applications in cancer therapy	57
CircSTX6 promotes pancreatic ductal adenocarcinoma progression by sponging miR-449b-5p and interacting with CUL2	56
Lipid nanoparticles deliver DNA-encoded biologics and induce potent protective immunity	56
Circular RNA circBNC2 inhibits tumorigenesis by modulating ferroptosis and acts as a nanotherapeutic target in prostate cancer	56
Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop	55
Transfer RNA-derived small RNAs in tumor microenvironment	55
CAR T cells: engineered immune cells to treat brain cancers and beyond	55
Deciphering the role of LGALS2: insights into tertiary lymphoid structure-associated dendritic cell activation and immunotherapeutic potential in breast cancer patients	54
Downregulation of Sod2 increases atypical flat lesions and dysplasia to advance pancreatic ductal adenocarcinoma	54
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer	53
circASAP1 induces renal clear cell carcinoma ferroptosis by binding to HNRNPC and thereby regulating GPX4	53
Writers, readers, and erasers RNA modifications and drug resistance in cancer	53
The mycobiome in human cancer: analytical challenges, molecular mechanisms, and therapeutic implications	52
Mechanisms and cross-talk of regulated cell death and their epigenetic modifications in tumor progression	52
The epigenetic hallmarks of immune cells in cancer	52
Clinical application of liquid biopsy in colorectal cancer: detection, prediction, and treatment monitoring	51
BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion	51
Advances in immunotherapy for triple-negative breast cancer	51
Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy	51
The journey of CAR-T therapy in hematological malignancies	50
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study	50
Traditional Chinese medicine in the treatment of breast Cancer	50
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy	50
Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC	49
CircLIFRSA/miR-1305/PTEN axis attenuates malignant cellular processes in non-small cell lung cancer by regulating AKT phosphorylation	49
Retraction Note: N6-methyladenosine induced mir-143-3p promotes the brain metastasis of lung cancer via regulation of VASH1	49
Commentary on “Epigenome-wide analysis across the development span of pediatric acute lymphoblastic leukemia: backtracking to birth”	49
Correction: CircNTNG1 inhibits renal cell carcinoma progression via HOXA5-mediated epigenetic silencing of Slug	49
M6A-Methylated circRAPGEF5 drives lung adenocarcinoma progression and metastasis via IGF2BP2/NUP160-mediated autophagy suppression	48
Ex vivo modelling of human colorectal cancer liver metastasis by normothermic machine perfusion	48
R-loops’ m6A modification and its roles in cancers	48
Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer	48